depemokimab-ulaa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
monoclonal antibodies 5799 None

Description:

MoleculeDescription

Molfile

Synonyms:

  • depemokimab
  • depemokimab-ulaa
  • GSK3511294
  • exdensur
Depemokimab targets human IL-5 with a binding affinity of 10.5 pM, thereby blocking the binding to the IL-5 receptor alpha expressed on the cell surface with picomolar potency (IC50 4 pM) in vitro. Depemokimab contains a triple amino acid substitution (YTE) in the fragment crystallisable (Fc) region which increases binding to the neonatal Fc receptor and thereby extends the half-life when compared to the IgG1 wildtype.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Dec. 16, 2025 FDA GlaxoSmithKline LLC
Dec. 22, 2025 PMDA GlaxoSmithKline LLC
Feb. 12, 2026 EMA GlaxoSmithKline Trading Services Limited

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R03DX12 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Other systemic drugs for obstructive airway diseases
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D019141 Respiratory System Agents
CHEBI has role CHEBI:65023 anti-asthmatic agent

Related Drugs by ATC class:

R03DX Other systemic drugs for obstructive airway diseases 10 drugs
amlexanoxbenralizumabeprozinolfenspiridemepolizumabomalizumabreslizumabroflumilastseratrodasttezepelumab

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Severe asthma indication 370221004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interleukin-5 Cytokine ANTAGONIST Kd 10.98 DRUG LABEL DRUG LABEL

External reference:

IDSource
4044476 VANDF
4044477 VANDF
C6056679 UMLSCUI
CHEBI:758351 CHEBI
CHEMBL4650469 ChEMBL_ID
2243274-14-6 SECONDARY_CAS_RN
44592 MMSL
d10350 MMSL
020312 NDDF
14305 IUPHAR_LIGAND_ID
11449 INN_ID
2729264 RXNORM
C000731964 MESH_SUPPLEMENTAL_RECORD_UI
D12169 KEGG_DRUG
D16EQP0KKH UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Exdensur HUMAN PRESCRIPTION DRUG LABEL 1 0173-0927 INJECTION, SOLUTION 100 mg SUBCUTANEOUS BLA 26 sections